Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of HDM3010 in nonsegmental vitiligo
CTR20243314Phase 3Active
- Sponsor
- 杭州中美华东制药有限公司 (Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.)
- Start
- Nov 2024
- Countries
- 1
01
Overview
A Phase 3 trial of HDM3010 in nonsegmental vitiligo, sponsored by 杭州中美华东制药有限公司 (Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.). Started Nov 2024; status: active.
02
Drugs
HDM3010
03
Conditions
nonsegmental vitiligo
Beyond the preview
Go deeper on CTR20243314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243314.